LENSAR, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
LNSR$4.62-15.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a)(1) Financial Statements
The following documents are included on pages F-1 through F-36 attached hereto and are filed as part of this Annual Report.
| AUDITED FINANCIAL STATEMENTS | |
|---|---|
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID 238) | F-1 |
| STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | F-2 |
| BALANCE SHEETS | F-3 |
| STATEMENTS OF CASH FLOWS | F-4 |
| STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | F-6 |
| NOTES TO FINANCIAL STATEMENTS | F-7 |
(a)(2) Financial Statement Schedules
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.
(a)(3) Exhibits
The following is a list of exhibits filed as part of this Annual Report.
| ExhibitNumber · Description · Form · File No. · Exhibit · Filing Date · Filed/FurnishedHerewith | |||||
|---|---|---|---|---|---|
| 1.2 | Sales Agreement, dated April 8, 2021 by and between LENSAR, Inc. and SVB Leerink LLC | Form S-3 | 333-255136 | 1.2 | 04/08/2021 |
| 2.1+ | Separation and Distribution Agreement between PDL BioPharma, Inc. and LENSAR, Inc. | Form 8-K | 001-39473 | 2.1 | 10/02/2020 |
| 2.2+ | Agreement and Plan of Merger, dated as of March 23, 2025, by and among LENSAR, Inc., Alcon Research, LLC, and VMI Option Merger Sub, Inc. | Form 8-K | 001-39473 | 2.1 | 03/24/2025 |
| 3.1 | Amended and Restated Certificate of Incorporation of LENSAR, Inc. | Form 8-K | 001-39473 | 3.1 | 10/02/2020 |
| 3.2 | Amended and Restated Bylaws of LENSAR, Inc. | Form 10-Q | 001-39473 | 3.2 | 11/07/2024 |
| 3.3 | Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023 | Form 8-K | 001-39473 | 3.1 | 05/18/2023 |
| ExhibitNumber · Description · Form · File No. · Exhibit · Filing Date · Filed/FurnishedHerewith | |||||
|---|---|---|---|---|---|
| 4.1 | Form of Certificate of Common Stock | Form 10/A | 001-39473 | 4.1 | 09/14/2020 |
| 4.3 | Registration Rights Agreement, dated May 12, 2023, between LENSAR, Inc. and NR-GRI Partners, LP | Form 8-K | 001-39473 | 10.2 | 05/18/2023 |
| 4.4 | Class A Common Stock Purchase Warrant, dated May 18, 2023 | Form 8-K | 001-39473 | 4.1 | 05/18/2023 |
| 4.5 | Class B Common Stock Purchase Warrant, dated May 18, 2023 | Form 8-K | 001-39473 | 4.2 | 05/18/2023 |
| 10.1+ | Transition Services Agreement between PDL BioPharma, Inc. and LENSAR, Inc. | Form 8-K | 001-39473 | 10.1 | 10/02/2020 |
| 10.2 | Tax Matters Agreement between PDL BioPharma, Inc. and LENSAR, Inc. | Form 8-K | 001-39473 | 10.2 | 10/02/2020 |
| 10.3# | 2020 Incentive Award Plan | Form S-8 | 333-249323 | 10.1 | 10/05/2020 |
| 10.4# | Form of Restricted Stock Agreement pursuant to 2020 Incentive Award Plan | Form S-8 | 333-249323 | 10.2 | 10/05/2020 |
| 10.5# | Form of Stock Option Agreement pursuant to 2020 Incentive Award Plan | Form 10-K | 001-39473 | 10.5 | 03/03/2022 |
| 10.6# | Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan | Form 10-K | 001-39473 | 10.6 | 03/03/2022 |
| 10.7# | Form of Performance Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan | Form 10-Q | 001-39473 | 10.2 | 05/09/2024 |
| 10.8# | Form of Performance Restricted Stock Unit Agreement – Director Deferral pursuant to 2020 Incentive Award Plan | Form 10-Q | 001-39473 | 10.3 | 05/09/2024 |
| 10.9# | 2020 Employee Stock Purchase Plan | Form 10/A | 001-39473 | 10.5 | 09/14/2020 |
| 10.10# | 2024 Employment Inducement Incentive Award Plan | Form 8-K | 001-39473 | 10.1 | 02/26/2024 |
| 10.11# | Form of Stock Option Agreement pursuant to 2024 Employment Inducement Incentive Award Plan | Form 8-K | 001-39473 | 10.2 | 02/26/2024 |
| 10.12# | Form of Restricted Stock Unit Agreement pursuant to 2024 Employment Inducement Incentive Award Plan | Form 8-K | 001-39473 | 10.3 | 02/26/2024 |
| 10.13# | Non-Employee Director Compensation Program, as amended | Form 10-Q | 001-39473 | 10.1 | 05/09/2024 |
| 10.14# | Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Nicholas Curtis | Form 10 | 001-39473 | 10.6 | 08/26/2020 |
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 10.15# | Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Alan Connaughton | Form 10 | 001-39473 | 10.7 | 08/26/2020 | |
| 10.16# | Employment Agreement, dated as of July 21, 2020, by and between LENSAR, Inc. and Thomas R. Staab II | Form 10 | 001-39473 | 10.8 | 08/26/2020 | |
| 10.17# | Form of Indemnification Agreement between LENSAR, Inc. and its directors and officers | Form 10 | 001-39473 | 10.9 | 08/26/2020 | |
| 10.18+ | Industrial Real Estate Lease, dated as of July 30, 2010, by and between LENSAR, Inc. and Challenger-Discovery, LLC, as amended as of March 15, 2016, December 16, 2016, August 20, 2020, September 9, 2020, December 17, 2024, and September 29, 2025 | Form 10-Q | 001-39473 | 10.1 | 11/06/2025 | |
| 10.19+ | Securities Purchase Agreement, dated May 12, 2023, between LENSAR, Inc. and NR-GRI Partners, LP | Form 8-K | 001-39473 | 10.1 | 05/15/2023 | |
| 10.20 | Form of Voting Agreement between NR-GRI Partners, LLP, and each of the executive officers and directors of LENSAR, Inc. | Form 8-K | 001-39473 | 10.1 | 05/18/2023 | |
| 10.21 | Termination and Mutual Release Agreement, dated March 16, 2026, by and among Alcon Research LLC, VMI Option Merger Sub, Inc. and LENSAR, Inc. | Form 8-K | 001-39473 | 10.1 | 03/17/2026 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm | * | ||||
| 31.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended | * | ||||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended | * | ||||
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ** | ||||
| 32.2 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ** | ||||
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date | Filed/FurnishedHerewith |
|---|---|---|---|---|---|---|
| 97.1 | Policy Relating to Recovery of Erroneously Awarded Compensation | Form 10-K | 001-39473 | 97.1 | 03/04/2024 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | * | ||||
| 104 | Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Certain schedules and attachments to certain of these exhibits have been omitted pursuant to Regulation S-K, Item 601(a)(5).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.